Exco InTouch Unveils Exco™ Valued Partner Network
News Mar 28, 2014
Exco InTouch will unveil the Exco™ Valued Partner Network at The Partnerships in Clinical Trials Congress taking place in Las Vegas between 30 March and 2 April 2014.
The company, which already services all of the world’s top ten pharmaceutical companies (ranked by 2013 revenues), will now highlight the competitive advantages, benefits and unique factors that mark out its novel Exco™ Valued Partner Network.
Exco InTouch, which will be exhibiting at stand 416, will also demonstrate its approach to BYOD (bring your own device) and more broadly to data capture and patient engagement services across clinical and late phase programs.
The Exco™ Valued Partner Network, has been created to enable Exco InTouch’s extensive pool of partners to benefit from collaborative activities and to experience the full range of services and capabilities offered first hand. Unique services, available to Exco InTouch partners, include the Exco™ Partner Cloud, a secure web portal that supports partner business development teams. The cloud enables partners to access tailored demonstrations, videos, case studies and co-branded materials, as well as providing information on their experience working together.
Other notable benefits of the network include innovation in the use of every day technologies, rapid access to patient centric solutions, a modular approach to system delivery, a BYOD cost saving model and enabling incorporation of ePRO capture into clinical studies.
In addition, the network provides valuable partner program benefits that range across governance, with executive team leaders assigned to champion each individual partnership, preferred flexible pricing, master services agreements, operational, marketing and strategic business support.
Tim Davis, CEO and co-founder of Exco InTouch commented “We are delighted to have the opportunity to highlight the extensive benefits and advantages that our partners can enjoy when they join our Exco™ Valued Partner Network. We are committed to strong partnerships with clients, seeing this as mutually beneficial to all concerned. We are always on the look-out for ways to optimize the value added services that we provide to customers in the field of data capture and patient engagement. Our partnership programs form an essential and integral component to our strategy for continuing to achieve this important objective.”
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE